Classification
Compound class	Synthetic organic
Approved drug?	Yes (FDA and EMA (2016))

IUPAC Name

4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

International Nonproprietary Names
INN number	INN
9925	venetoclax

Synonyms

ABT-199 | GDC-0199 | Venclexta® | Venclyxto®

Comments

Venetoclax is a BH3 mimetic that selectively targets Bcl-2 [4], utilised for its pro-apoptotic activity. It is noteworthy that venetoclax is the first approved medicine designed to induce a natural process that helps cells self-destruct. The IUPAC name provided by PubChem matches 'Example 5' claimed in patent US8580794 [1].

Database Links
CAS Registry No.	1257044-40-8
ChEMBL Ligand	CHEMBL3137309
GtoPdb PubChem SID	252166530
PubChem CID	49846579
Search Google for chemical match using the InChIKey	LQBVNQSMGBZMKD-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	LQBVNQSMGBZMKD
Search PubMed clinical trials	venetoclax
Search PubMed titles	venetoclax
Search PubMed titles/abstracts	venetoclax
Search UniChem for chemical match using the InChIKey	LQBVNQSMGBZMKD-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	LQBVNQSMGBZMKD